BIOMAT Database Logo BIOMAT Database Logo

Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer. 2020

Liang Jin, and Kai Chen, and Cui Tan, and Jianbin Li, and Jiayue Luo, and Yaping Yang, and Yudong Li, and Shunying Li, and Liling Zhu, and Yue Hu, and Fengtao Liu, and Qiuting You, and Min Peng, and Zefei Jiang, and Qiang Liu
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.

This study aimed to investigate whether an immunohistochemical prognostic model (IHC4 score) can predict the prognosis and the chemotherapy benefit in patients with estrogen receptor-positive (ER+)/human epidermal growth receptor 2-negative (HER2-) metastatic breast cancer (MBC). We developed a method to calculate the modified IHC4 (mIHC4) scores based on routine pathological reports and compared them with the original IHC4 scores that were much more difficult to calculate. Univariate and multivariate analyses were used to study the prognostic factors of progression-free survival (PFS) and overall survival (OS). The predictive value of mIHC4 score was also investigated. The Sun Yat-sen Memorial Hospital data set included 315 patients with newly diagnosed ER+ MBC with a median follow-up of 25.6 months. Univariate and multivariate analysis showed that higher mIHC4 scores in metastatic lesions, but not the ones in primary tumors, were significantly associated with worse PFS and OS. The prognostic value of mIHC4 scores for PFS was validated using an independent Chinese Society of Clinical Oncology- Breast Cancer (CSCO-BC) data set. More importantly, subpopulation treatment effect pattern plot analysis showed that first-line endocrine therapy achieved better PFS and OS than chemotherapy in low-risk patients with ER+/HER2- MBC, whereas first-line chemotherapy was associated with improved PFS and OS compared with endocrine therapy in high-risk ones. The predictive value of mIHC4 score for PFS in selecting first-line endocrine therapy versus chemotherapy was also confirmed in the CSCO-BC data set. mIHC4 scores in metastatic lesions are prognostic for the PFS and OS in patients with ER+ MBC. Low or high mIHC4 score may indicate the survival benefit in choosing first-line endocrine therapy or chemotherapy in patients with ER+/HER2- MBC, respectively. The modified IHC4 (mIHC4) score is easy to implement and able to predict patients with advanced and/or metastatic breast cancer. In addition, with the help of the mIHC4 score, physicians might be able to recommend chemotherapy or endocrine therapy as the first-line treatment for patients with high and low risk as predicted by the mIHC4 score.

UI MeSH Term Description Entries
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077982 Progression-Free Survival Length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but the disease does not get worse. Event-Free Survival,Event Free Survival,Progression Free Survival,Survival, Event-Free,Survival, Progression-Free
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D018719 Receptor, ErbB-2 A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member. HER-2 Proto-Oncogene Protein,Proto-Oncogene Protein HER-2,Proto-Oncogene Protein p185(neu),c-erbB-2 Protein,erbB-2 Proto-Oncogene Protein,erbB-2 Receptor Protein-Tyrosine Kinase,neu Proto-Oncogene Protein,Antigens, CD340,CD340 Antigen,Erb-b2 Receptor Tyrosine Kinases,Metastatic Lymph Node Gene 19 Protein,Neu Receptor,Oncogene Protein HER-2,Proto-Oncogene Proteins c-erbB-2,Proto-oncogene Protein Neu,Receptor, Neu,Receptors, erbB-2,Tyrosine Kinase-type Cell Surface Receptor HER2,p185(c-neu),p185erbB2 Protein,CD340 Antigens,Erb b2 Receptor Tyrosine Kinases,ErbB-2 Receptor,HER 2 Proto Oncogene Protein,Oncogene Protein HER 2,Proto Oncogene Protein HER 2,Proto Oncogene Proteins c erbB 2,Proto-Oncogene Protein, HER-2,Proto-Oncogene Protein, erbB-2,Proto-Oncogene Protein, neu,Tyrosine Kinase type Cell Surface Receptor HER2,c erbB 2 Protein,erbB 2 Proto Oncogene Protein,erbB 2 Receptor Protein Tyrosine Kinase,erbB-2 Receptors,neu Proto Oncogene Protein

Related Publications

Liang Jin, and Kai Chen, and Cui Tan, and Jianbin Li, and Jiayue Luo, and Yaping Yang, and Yudong Li, and Shunying Li, and Liling Zhu, and Yue Hu, and Fengtao Liu, and Qiuting You, and Min Peng, and Zefei Jiang, and Qiang Liu
Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer.
July 2017, Breast cancer research and treatment,
Liang Jin, and Kai Chen, and Cui Tan, and Jianbin Li, and Jiayue Luo, and Yaping Yang, and Yudong Li, and Shunying Li, and Liling Zhu, and Yue Hu, and Fengtao Liu, and Qiuting You, and Min Peng, and Zefei Jiang, and Qiang Liu
A combination of Nottingham prognostic index and IHC4 score predicts pathological complete response of neoadjuvant chemotherapy in estrogen receptor positive breast cancer.
December 2016, Oncotarget,
Liang Jin, and Kai Chen, and Cui Tan, and Jianbin Li, and Jiayue Luo, and Yaping Yang, and Yudong Li, and Shunying Li, and Liling Zhu, and Yue Hu, and Fengtao Liu, and Qiuting You, and Min Peng, and Zefei Jiang, and Qiang Liu
Prognostic value of the 21-gene recurrence score for regional recurrence in patients with estrogen receptor-positive breast cancer.
August 2021, Breast cancer research and treatment,
Liang Jin, and Kai Chen, and Cui Tan, and Jianbin Li, and Jiayue Luo, and Yaping Yang, and Yudong Li, and Shunying Li, and Liling Zhu, and Yue Hu, and Fengtao Liu, and Qiuting You, and Min Peng, and Zefei Jiang, and Qiang Liu
Predictive Value of IHC4 Score for Pathological Response to Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer.
January 2015, Asian Pacific journal of cancer prevention : APJCP,
Liang Jin, and Kai Chen, and Cui Tan, and Jianbin Li, and Jiayue Luo, and Yaping Yang, and Yudong Li, and Shunying Li, and Liling Zhu, and Yue Hu, and Fengtao Liu, and Qiuting You, and Min Peng, and Zefei Jiang, and Qiang Liu
Prognostic value of estrogen receptor determinations in patients with breast cancer.
November 1978, Cancer research,
Liang Jin, and Kai Chen, and Cui Tan, and Jianbin Li, and Jiayue Luo, and Yaping Yang, and Yudong Li, and Shunying Li, and Liling Zhu, and Yue Hu, and Fengtao Liu, and Qiuting You, and Min Peng, and Zefei Jiang, and Qiang Liu
Efficacy of fulvestrant in treating postmenopausal patients with estrogen receptor-positive metastatic breast cancer and prognostic analysis.
January 2021, Journal of B.U.ON. : official journal of the Balkan Union of Oncology,
Liang Jin, and Kai Chen, and Cui Tan, and Jianbin Li, and Jiayue Luo, and Yaping Yang, and Yudong Li, and Shunying Li, and Liling Zhu, and Yue Hu, and Fengtao Liu, and Qiuting You, and Min Peng, and Zefei Jiang, and Qiang Liu
Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.
February 2019, The oncologist,
Liang Jin, and Kai Chen, and Cui Tan, and Jianbin Li, and Jiayue Luo, and Yaping Yang, and Yudong Li, and Shunying Li, and Liling Zhu, and Yue Hu, and Fengtao Liu, and Qiuting You, and Min Peng, and Zefei Jiang, and Qiang Liu
Comparison of the Modified Immunohistochemical Marker Score and 21-Gene Recurrence Score Assay in Patients with Estrogen Receptor-Positive Breast Cancer.
January 2022, Oncology,
Liang Jin, and Kai Chen, and Cui Tan, and Jianbin Li, and Jiayue Luo, and Yaping Yang, and Yudong Li, and Shunying Li, and Liling Zhu, and Yue Hu, and Fengtao Liu, and Qiuting You, and Min Peng, and Zefei Jiang, and Qiang Liu
Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer.
November 2019, Clinical epigenetics,
Liang Jin, and Kai Chen, and Cui Tan, and Jianbin Li, and Jiayue Luo, and Yaping Yang, and Yudong Li, and Shunying Li, and Liling Zhu, and Yue Hu, and Fengtao Liu, and Qiuting You, and Min Peng, and Zefei Jiang, and Qiang Liu
Expression and prognostic value of estrogen receptor β in patients with triple-negative and triple-positive breast cancer.
June 2015, Experimental and therapeutic medicine,
Copied contents to your clipboard!